Cresco Labs Continues Track Record of Delivering Strong Operating Cash Flow
First Quarter 2025 Highlights
First quarter revenue of $166 million. First quarter operating cash flow of $30 million and Free Cash Flow 1 of $25 million.
Gross profit of $79 million. Adjusted gross profit 1 of $82 million; and an Adjusted gross margin 1 of 49% of revenue.
SG&A of $58 million or 35% of revenue.
Net loss of $15 million.
First quarter Adjusted EBITDA 1 of $36 million and Adjusted EBITDA margin 1 of 22%.
Retained the No. 1 share position in multiple billion dollar markets. 2
Management Commentary
"We entered 2025 with the flexibility and financial strength needed to navigate market volatility, complete our debt refinancing, and remain both strategic and patient as we invest thoughtfully for long-term growth."
In Q1, we delivered $166 million in revenue, reflecting our successful plan to reduce AR exposure by limiting sales to wholesale accounts with credit risk. We generated $82 million in adjusted gross profit, and $36 million in Adjusted EBITDA. Most importantly, these actions translate into strong cash results. We generated $30 million in operating cash flow and ended the quarter with $162 million in cash, our highest balance in the past three years.
"We're focused on ensuring our balance sheet remains in the strongest possible position to support long-term value creation," said Charlie Bachtell, Cresco Labs CEO and co-founder. "By staying disciplined and thoughtful in how we deploy capital, we're positioning Cresco Labs to drive margin expansion, gain market share, and invest in sustainable growth when the right opportunities arise."
Balance Sheet, Liquidity, and Other Financial Information
As of March 31, 2025, current assets were $311 million, including cash, cash equivalents, and restricted cash of $159 million. The Company had senior secured term loan debt, net of discount and issuance costs, of $353 million and a mortgage loan, net of discount and issuance costs of $18 million.
Total shares on a fully converted basis to Subordinate Voting Shares were 484,592,240 as of March 31, 2025.
Conference Call and Webcast
The Company will host a conference call and webcast to discuss its financial results on Monday, June 2, 2025, at 8:30am Eastern Time (7:30am Central Time). The conference call may be accessed via webcast or by dialing 1-833-470-1428 (US Toll Free) or 1-404-975-4839 (US Local), providing access code 671160. Archived access to the webcast will be available for one year on Cresco Labs' investor website, here.
Consolidated Financial Statements
The financial information reported in this press release is based on unaudited management prepared financial statements for the quarter ended March 31, 2025. These financial statements have been prepared in accordance with U.S. GAAP. The Company expects to file its unaudited condensed interim consolidated financial statements for the quarter ended March 31, 2025, on SEDAR+ and EDGAR on or about May 30, 2025. Accordingly, such financial information may be subject to change. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes between the information contained in this press release and the consolidated financial statements it files on SEDAR+ and EDGAR, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company's financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company's filed financial statements. The making of a modifying or superseding statement shall not be deemed an admission, for any purposes, that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Further, the reader should refer to the additional disclosures in the Company's audited financial statements for the year ended December 31, 2024, filed on SEDAR+ and EDGAR.
Cresco Labs references certain non-GAAP financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers. Please see the 'Non-GAAP Financial Measures' section below for more detailed information.
Non-GAAP Financial Measures
This release reports its financial results in accordance with U.S. GAAP and includes certain non-GAAP financial measures that do not have standardized definitions under U.S. GAAP. The non-GAAP measures include: Earnings before interest, taxes, depreciation, and amortization ('EBITDA'); Adjusted EBITDA; Adjusted EBITDA margin; Adjusted gross profit; Adjusted gross profit margin; Adjusted selling, general, and administrative expenses ('Adjusted SG&A'), Adjusted SG&A margin; and Free Cash Flow are non-GAAP financial measures and do not have standardized definitions under U.S. GAAP. The Company defines these non-GAAP financial measures as follows: EBITDA as net loss (income) before interest, taxes, depreciation, and amortization; Adjusted EBITDA as EBITDA less other (expense) income, net, fair value mark-up for acquired inventory, adjustments for acquisition and non-core costs, impairment and share-based compensation; Adjusted EBITDA Margin as Adjusted EBITDA divided by revenues, net; Adjusted gross profit as gross profit less fair value mark-up for acquired inventory and adjustments for acquisition and non-core costs; Adjusted gross profit margin as Adjusted gross profit divided by revenues, net; Adjusted SG&A as SG&A less adjustments for acquisition and non-core costs; Adjusted SG&A margin as Adjusted SG&A divided by revenues, net; and Free Cash Flow as Net cash provided by operating activities less purchases of property and equipment and proceeds from tenant improvement allowances. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with U.S. GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with U.S. GAAP and may not be comparable to similar measures presented by other issuers. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the U.S. GAAP financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.
About Cresco Labs Inc.
Cresco Labs' mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy's, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs' journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.
Forward-Looking Statements
This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, 'forward-looking statements'). Such forward-looking statements are not representative of historical facts or information or current condition but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' or 'continue,' or the negative of those forms or other comparable terms. The Company's forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under 'Risk Factors' in the Company's Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company's forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs' shares, nor as to the Company's financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company's forward-looking statements contained herein, whether as a result of new information, any future event, or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
Cresco Labs Inc.
Summarized Consolidated Statements of Financial Position
As of March 31, 2025 and December 31, 2024
($ in thousands)
March 31, 2025
December 31, 2024
(unaudited)
Cash, cash equivalents, and restricted cash (current)
$
158,867
$
141,003
Other current assets
152,226
153,254
Property and equipment, net
338,399
344,846
Intangible assets, net
293,317
293,994
Goodwill
283,484
283,484
Other non-current assets
137,808
138,774
Total assets
$
1,364,101
$
1,355,355
Total current liabilities
$
113,197
$
94,338
Total non-current liabilities
875,335
872,841
Total shareholders' equity
375,569
388,176
Total liabilities and shareholders' equity
$
1,364,101
$
1,355,355
Expand
Cresco Labs Inc.
Unaudited Reconciliation of SG&A to Adjusted SG&A (Non-GAAP)
For the Three Months Ended March 31, 2025, December 31, 2024, and March 31, 2024
For the Three Months Ended
($ in thousands)
March 31,
2025
December 31,
2024
March 31,
2024
Selling, general, and administrative
$
57,811
$
56,030
$
54,013
Adjustments for acquisition and other non-core costs
4,841
2,299
2,297
Adjusted SG&A (Non-GAAP)
$
52,970
$
53,731
$
51,716
Adjusted SG&A % (Non-GAAP)
32.0
%
30.5
%
28.1
%
Expand
Cresco Labs Inc.
Unaudited Reconciliation of Net (Loss) Income to Adjusted EBITDA (Non-GAAP)
For the Three Months Ended
($ in thousands)
March 31,
2025
December 31,
2024
March 31,
2024
Net (loss) income 1
$
(15,234
)
$
439
$
(2,055
)
Depreciation and amortization
12,906
13,904
15,331
Interest expense, net
14,824
13,079
14,071
Income tax expense
14,316
2,616
18,003
EBITDA (Non-GAAP)
$
26,812
$
30,038
$
45,350
Other (income) expense, net
(317
)
3,272
(856
)
Adjustments for acquisition and other non-core costs
7,015
4,493
4,470
Share-based compensation
2,723
3,705
4,197
Adjusted EBITDA (Non-GAAP)
$
36,233
$
41,508
$
53,161
Adjusted EBITDA % (Non-GAAP)
21.9
%
23.6
%
28.8
%
1 Net (loss) income includes amounts attributable to non-controlling interests.
Expand
Cresco Labs Inc.
Unaudited Summarized Consolidated Statements of Cash Flows
For the Three Months Ended March 31, 2025, December 31, 2024, and March 31, 2024
For the Three Months Ended
($ in thousands)
March 31,
2025
December 31,
2024
March 31,
2024
Net cash provided by operating activities
$
30,463
$
29,486
$
36,471
Net cash used in investing activities
(6,869
)
(3,013
)
(5,677
)
Net cash used in financing activities
(5,733
)
(42,034
)
(11,149
)
Effect of foreign currency exchange rate changes on cash and cash equivalents
2
9
(13
)
Net increase in cash and cash equivalents
$
17,863
$
(15,552
)
$
19,632
Cash and cash equivalents and restricted cash, beginning of period
144,255
159,806
108,520
Cash and cash equivalents and restricted cash, end of period
$
162,118
$
144,254
$
128,152
Expand
Cresco Labs Inc.
Unaudited Reconciliation of Operating Cash Flow to Free Cash Flow (Non-GAAP)
For the Three Months Ended March 31, 2025, December 31, 2024, and March 31, 2024
For the Three Months Ended
($ in thousands)
March 31,
2025
December 31,
2024
March 31,
2024
Net cash provided by operating activities
$
30,463
$
29,486
$
36,471
Purchases of property and equipment
(5,818
)
(3,204
)
(3,782
)
Proceeds from tenant improvement allowances
50
439
478
Free Cash Flow (Non-GAAP)
$
24,695
$
26,721
$
33,167
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
29 minutes ago
- Business Upturn
Atlanticus Holdings Corporation Announces Pricing of $400 million Senior Notes Offering
ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) ('Atlanticus,' the 'Company,' 'we' or 'our') today announced that it has successfully priced an offering of $400,000,000 aggregate principal amount of 9.750% Senior Notes due 2030 (the 'Notes') to be issued by the Company and guaranteed by certain of its domestic subsidiaries. The Notes are expected to be issued on August 20, 2025, subject to the satisfaction or waiver of customary closing conditions. The Company intends to use the net proceeds from the offering of the Notes (i) to repay amounts outstanding under its recourse warehouse facilities, (ii) for general corporate purposes, including to fund future acquisitions of portfolios and associated businesses and to fund the partial or full repayment of its 6.125% Senior Notes due 2026 on or prior to maturity and (iii) to pay fees and expenses in connection with the offering. The Notes and the related guarantees are being offered and sold to persons reasonably believed to be 'qualified institutional buyers' pursuant to Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act') and to certain non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act. The Notes and the related guarantees have not been registered for sale under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes, the related guarantees or any other security, and shall not constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful. About Atlanticus Holdings Corporation (NASDAQ: ATLC) Empowering Better Financial Outcomes for Everyday Americans AtlanticusTM technology enables bank, retail, and healthcare partners to offer more inclusive financial services to everyday Americans through the use of proprietary analytics. We apply the experience gained and infrastructure built from servicing over 20 million customers and over $44 billion in consumer loans over more than 25 years of operating history to support lenders that originate a range of consumer loan products. These products include retail and healthcare private label credit and general purpose credit cards marketed through our omnichannel platform, including retail point-of-sale, healthcare point-of-care, direct mail solicitation, internet-based marketing, and partnerships with third parties. Additionally, through our Auto Finance subsidiary, Atlanticus serves the individual needs of automotive dealers and automotive non-prime financial organizations with multiple financing and service programs. Forward-Looking Statements This press release contains forward-looking statements that reflect the Company's current views with respect to the closing of the Notes and the use of proceeds therefrom. You generally can identify these statements by the use of words such as 'outlook,' 'potential,' 'continue,' 'may,' 'seek,' 'approximately,' 'predict,' 'believe,' 'expect,' 'plan,' 'intend,' 'estimate' or 'anticipate' and similar expressions or the negative versions of these words or comparable words, as well as future or conditional verbs such as 'will,' 'should,' 'would,' 'likely' and 'could.' These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those included in the forward-looking statements. These risks and uncertainties include those risks described in the Company's filings with the Securities and Exchange Commission and include, but are not limited to, risks related to the Company's ability to satisfy the conditions to closing the Notes; the Company's ability to retain existing, and attract new, merchant partners and funding sources; changes in market interest rates; increases in loan delinquencies; its ability to operate successfully in a highly regulated industry; the outcome of litigation and regulatory matters; the effect of management changes; cyberattacks and security vulnerabilities in its products and services; and the Company's ability to compete successfully in highly competitive markets. The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, the Company disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In light of these risks and uncertainties, there is no assurance that the events or results suggested by the forward-looking statements will in fact occur, and you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release or as of the date to which they refer, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law. Contact:Investor Relations(770) 828-2000 [email protected]
Business Upturn
29 minutes ago
- Business Upturn
Daily Journal Corporation Provides Additional Public Access to its New Form 8-K
LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) — Daily Journal Corporation is issuing this press release to provide additional public access to the Form 8-K it filed earlier today with the Securities and Exchange Commission in response to the continued interest in our software accounting from Buxton Helmsley USA, Inc. and its Chairman and CEO, Alexander E. Parker. Below is the text of our Form 8-K. Item 8.01 Other Events. In July, the Company started receiving letters from an investment adviser called Buxton Helmsley USA, Inc. ('BuHeUI') alleging that the Company has been improperly expensing its software development costs and should be capitalizing them under the accounting requirements set forth in ASC 985-20, Costs of Software to be Sold, Leased or Marketed ('ASC 985-20'). According to BuHeUI and its Chairman and CEO, Alexander E. Parker, switching from expensing development costs to capitalizing them would unlock value for Company shareholders, and he demanded a 15% share in the appreciation of the Company's stock price as compensation for his idea. He pointed to Tyler Technologies and Galaxy Gaming as proof that other software companies 'properly comply' with ASC 985-20 by capitalizing their development costs. Simply stated, Mr. Parker got it wrong. Following receipt of his initial letters, the Audit Committee of the Board re-reviewed the applicable accounting guidance and the Company's practices with its accountants and with third party experts. All agree that the Company has been correctly accounting for its software development costs in accordance with ASC 950-20. To understand Mr. Parker's mistake requires a brief explanation of the relevant accounting standards. Historically, most software companies accounted for development costs under ASC 985-20, which establishes the requirements a company must meet to capitalize those costs when associated with software to be sold or licensed to a third party. A company is only allowed to capitalize costs incurred during the period after the technological feasibility of the software has been established and prior to its general release. Ironically, one of the main accounting concerns in the past had been that companies would capitalize too much and too soon, because it helped improve their short-term earnings by reducing expenses and moving them to the balance sheet (or, as Mr. Parker might say, 'unlocking value'). Moreover, the process of software development has substantially evolved at many companies since the initial ASC 985-20 guidance was issued, with most companies now applying an agile software development methodology that emphasizes iterative development in a continually changing environment. This results in the capitalization window between technological feasibility and general release to be so short that few companies incur any material amount of costs that would qualify for capitalization. The Company's software products and our agile development efforts are in that camp. In addition, with the growing popularity of software-as-a-service (or 'SaaS'), companies that make predominately SaaS software take the position that their software is being developed for 'internal use' because their customers are purchasing access to a hosted product, rather than actually receiving the software. This is important because 'internal use' software is accounted for under an entirely different accounting standard : ASC 350-40, Internal Use Software ('ASC 350-40'). You should expect to see more capitalized costs for a SaaS company taking this position because ASC 350-40 provides that eligible costs can be capitalized over a typically much longer development window compared to the short window for 'external use' software (like ours) under ASC 985-20. Neither Galaxy Gaming nor Tyler Technologies expressly states in its public filings which accounting guidance it used to capitalize costs, and we suspect Mr. Parker simply assumed it was ASC 985-20. He appears to have been mistaken. Galaxy refers in its 10-K to ' internally developed software ' in its consolidated statements of cash flows, and Tyler refers in its 10-K to the 'amortization of software development for internal use ' in its G&A expenses. This means, in both cases, that they are likely capitalizing costs for 'internal use software' under ASC 350-40 – not ASC 985-20. And, yes, the Company does offer some SaaS enhancements to our eSeries products, but the Company would not qualify for ASC 350-40 treatment because the vast majority of our software continues to be licensed to customers (almost entirely courts and government agencies) to whom we deliver the software, with those customers arranging for hosting based on their own security and operational needs. Lest there be any doubt, the Company has and will continue to expense development costs when that is the proper thing to do, and it will capitalize any such costs in the future when that is the proper thing to do. It will also disclose any specific R&D costs separate and apart from other expenses, if material. Mr. Parker may never admit that he was wrong or that he simply misunderstood why other software companies are capitalizing development costs, given that they appear to be using a completely different accounting standard than the one cited in each of his nine letters so far. At a minimum, he should be embarrassed for demanding compensation from the Company, alleging securities law violations, calling for the resignations of the CEO and CFO, insisting on being given two Board seats, reporting the Company to the enforcement division of the SEC, referring the Company's auditor to the Public Company Accounting Oversight Board, alleging wild conflicts of interest by our directors, and falsely claiming defamation – all based on a mistake. Mr. Munger once offered some sage advice that may be useful for Mr. Parker, who is currently advertising on his website for new investors to entrust their money with him and his approach: 'There's no way that you can live an adequate life without many mistakes. In fact, one trick in life is to get so you can handle mistakes. Failure to handle psychological denial is a common way for people to go broke.' On behalf of its shareholders, the Company calls on Mr. Parker to do the right thing and end his misplaced, self-serving attacks on the Company and its people, so that they can focus their attention on unlocking actual business value. # Contact: Jessica Marshall (778) 716-6706 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
39 minutes ago
- Business Wire
AM Best to Speak in a Session at the 2025 CAS China Insurance Summit
HONG KONG--(BUSINESS WIRE)-- AM Best will participate in a session during the Casualty Actuarial Society's fourth annual China Insurance Summit, taking place on Aug. 22, 2025, at the Mingyu Chengdu Dongda Hotel in Chengdu, China. Christie Lee, senior director, head of analytics, will speak at 2:30 p.m. CST in a session titled, 'Reinsurance Market Development Trends.' Additional AM Best attendees will include Judy Li, market development analyst, and Lucie Huang, senior financial analyst. Participants will be able to attend in-person or virtually. The event will be conducted in Mandarin, with limited sessions in English. This summit will feature an action-packed schedule with a broad range of topics. To learn more about the summit, visit the event website. To schedule a meeting, please contact Judy Li, or James Chan, Copyright © 2025 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
